Non-invasive whole-body imaging using near-infrared (NIR) fluorescence has been broadly developed because of its low tissue absorption and scattering compared to that observed with visible fluorescence. [1] [2] [3] Recently, second-NIR fluorescence (1000-1500 nm) has been used for non-invasive in vivo imaging. [4] [5] [6] [7] Second-NIR fluorescence imaging has advantages over traditional NIR fluorescence imaging (700-900 nm) such as reduced light scattering and minimal autofluorescence. 5 For the second-NIR fluorescence imaging, semiconductor quantum dots (QDs) such as PbS, [8] [9] [10] [11] [12] [13] PbSe, 10 and Ag 2 S 14 are promising fluorescent probes because of their strong fluorescence and photostability at wavelengths in the range of 1000-1500 nm. However, fluorescence imaging using second-NIR QDs usually encounters two major difficulties. First, the preparation of the QD-based fluorescent probe needs multiple synthetic steps such as QD formation, surface modification and biomolecule conjugation. [8] [9] [10] [11] [12] [13] [14] Second, the fluorescence detectors of conventional microscope systems do not support second-NIR fluorescence imaging. 5, 6, 15, 16 To overcome these problems, we have developed a dual (visible and second-NIR) emission QD probe that can be used for both cellular and noninvasive whole-body imaging. In this communication, we report a facile synthesis of recombinant protein functionalized PbS QDs with dual emission (visible and second-NIR fluorescence), which have a binding ability for antibody molecules (IgG) in aqueous solution.
We have used an enhanced green fluorescent protein (EGFP)-Protein G B1 domain 17 tagged with glutathione S-transferase (GST) as a template 18, 19 (GST-EGFP-GB1; 61.7 kDa, see ESI †) to grow PbS QDs in the aqueous phase (Scheme 1). The recombinant protein, GST-EGFP-GB1 was genetically designed and prepared by a conventional method for recombinant protein synthesis in Escherichia coli. Protein G is a cell surface protein of Streptococcus and its B1 domain binds to the Fc region of immunoglobulin G (IgG). It has been widely used for detecting and purifying IgG antibodies. 17 Particularly in cancer molecular imaging, a receptor-targeting antibody can act as a powerful tool via the conjugation of antibodies to the QD surface. In this case, a large amount of antibodies was used for conjugation to QDs. 2, 11, 13 Since the GST-EGFP-GB1-coated QDs contain a protein G B1 domain, they can easily bind to antibody molecules by a simple mixing of antibodies with the QD solution. [20] [21] [22] The fluorescent protein EGFP is chosen to add a function of visible fluorescence emission to the second-NIR emitting PbS QDs. This dual-emitting property of the QDs enables a conduction of high-resolution cellular confocal imaging by EGFP fluorescence in addition to the deep-tissue imaging by second-NIR fluorescence. Thus the GST-EGFP-GB1-coated QDs make it possible to correlate the intracellular localization of probes with bio-distribution in the whole mouse body. GST-EGFP-GB1-coated PbS QDs can be prepared by using a protein-mediated QD synthetic method (Scheme 1). 18, 19 The synthesis is carried out by reacting GST-EGFP-GB1 with lead acetate (Pb(Ac) 2 the GST-EGFP-GB1 protein. By this synthetic method, we can easily prepare protein-coated PbS QDs within 10 minutes. To characterize the GST-EGFP-GB1-coated PbS QDs, we have analysed their transmission electron microscopic (TEM) images, dynamic light scattering (DLS), and fluorescence/absorption spectra. Fig. 1a shows TEM images of GST-EGFP-GB1-coated PbS QDs. The PbS QDs have spherical shapes (ca. 5 nm) with a selected area electron diffraction (SAED) pattern and lattice fringes, confirming the crystalline nature of the PbS QDs with a cubic structure. 23 The hydrodynamic size of the PbS QDs was determined to be ca. 30 nm in diameter by DLS (Fig. 1b) . This value is ca. 25 nm larger than that determined by TEM analysis. This indicates that the GST-EGFP-GB1 fusion proteins (10 nm in diameter) surround the surface of the PbS QDs. The fluorescence spectrum of the GST-EGFP-GB1-coated PbS QDs showed dual emission, with the visible emission at 515 nm and a second-NIR emission at 1150 nm, under excitation at 450 nm ( Fig. 1c and S1, S2 in ESI †). The visible and NIR fluorescence emissions are from EGFP proteins and PbS QDs, respectively. The quantum yield (QY) of the second-NIR fluorescence of PbS QDs (1150 nm emission peak) was measured by a relative method with CdSeTe/CdS QDs (840 nm emission, QY = 50%) as a standard (see the Experimental section in ESI †). QY was determined to be 10% in water.
The binding ability of GST-EGFP-GB1-coated QDs towards antibody was confirmed using fluorescence correlation spectroscopy (FCS). tion for all three samples. Binding between the Protein G B1 domain and the antibody was confirmed by the change in the diffusion time of the GST-EGFP-GB1-coated QDs (0.82 ms) and a mixture of anti-HER2 antibody + GST-EGFP-GB1-coated QDs (1.26 ms). Based on the Einstein-Stokes equation, hydrodynamic diameters were estimated to be 23 nm for GST-EGFP-GB1-coated QDs and 35 nm for the anti-HER2 antibody + GST-EGFP-GB1-coated QDs complex. This result confirms the binding of anti-HER2 antibody to the GST-EGFP-GB1-coated QDs. It is also confirmed by the analysis of the photon counts per particle (CPP), expressing the fluorescence brightness of the single-particle. The CPP value of the GST-EGFP-GB1-coated QDs is two times higher than that of the free GST-EGFP-GB1 protein (inset of Fig. 2 ), indicating that at least two GST-EGFP-GB1 molecules are included in one PbS QD. It should also be noted that the CPP value of the mixture of anti-HER2 antibody + GST-EGFP-GB1-coated QDs is four times higher than that of the free GST-EGFP-GB1 protein. This indicates that the complex of antibody + QDs contain two GST-EGFP-GB1-coated QDs due to the inter-particle binding of the GB1 domain by their respective QDs.
To demonstrate the capability of GST-EGFP-GB1-coated QDs, we first performed the fluorescence imaging of breast tumor cells in the visible and second-NIR regions. For fluorescence imaging, we have used a human breast tumor cell line (KPL-4) 25 over-expressing HER2 on its cell membrane. Fig. 3b shows a second-NIR fluorescence image of KPL-4 cells stained with anti-HER2 antibody and GST-EGFP-GB1-coated QDs. The second-NIR fluorescence (excitation: 670 nm, emission: 1300 nm, 6.3× magnification) is clearly observed after a 30 min incubation of KPL-4 cells with anti-HER2 antibody and GST-EGFP-GB1-coated QDs (Fig. 3b) . Each bright spot represents a single-cell. These results show that the GST-EGFP-GB1-coated QDs act as a dual-emission molecular targeting probe with visible and second-NIR fluorescence.
GST-EGFP-GB1-coated QDs showed low cytotoxicity in HeLa cells at the concentration (<250 nM) used for in vitro and in vivo fluorescence imaging (Fig. S4 in ESI †) . Next, we performed a second-NIR fluorescence imaging of the breast tumor implanted KPL-4 cells in a nude mouse. An aqueous solution (200 μL) of GST-EGFP-GB1-coated QDs (1 μM) mixed with anti-HER2 antibody was injected into the tail vein of a live mouse, and second-NIR fluorescence images (excitation: 670 nm, emission: 1300 nm) were taken after 48 hours of QD injection (Fig. 4) . As shown in Fig. 4c , intense second-NIR fluorescence from the breast tumor is clearly observed, compared to the control without QD injection ( Fig. S5 in ESI †) . This indicates the accumulation of anti-HER2 antibody binding QDs in the tumor. In contrast, there is no significant second-NIR fluorescence in the area without tumors (Fig. 4b) . To confirm actual accumulation of the QDs in the breast tumor cells, we carried out ex vivo fluorescence imaging of an isolated tumor at a higher magnification by a confocal microscope and a second-NIR microscope (Fig. 4d , e, and S6 in ESI †). Compared with the negative control without QDs injection (Fig. 4d) , intense fluorescence of EGFP emitting from the anti-HER2 antibody-conjugated QDs was observed in the breast tumor (Fig. 4e) . This finding indicates that the conjugates of anti-HER2 antibody and GST-EGFP-GB1-coated QDs pass through the blood vessels of the breast tumor and bind to the HER2 receptors on the tumor cells.
In summary, we have demonstrated a one-step facile method for preparing GST-EGFP-GB1 protein-coated PbS QDs with a dual emission of visible (515 nm) and second-NIR fluorescence (1150 nm). The PbS QDs have two molecules of GST-EGFP-GB1 protein per QD particle, and they can easily bind IgG antibodies via their GB1 domain. We have demonstrated that the GST-EGFP-GB1-coated PbS QDs have a dualcolor probe capability for the fluorescence molecular imaging of breast tumors at the cellular and whole-body level. An important feature of this work is that the GST-EGFP-GB1-coated QDs make it possible to correlate the cellular distribution of QD probes with their bio-distribution in the whole body. These dual emission PbS QDs with antibody binding ability can be extended to a variety of in vitro and in vivo tumor imaging techniques by constructing conjugates between specific antibodies for tumors and the GST-EGFP-GB1 proteincoated PbS QDs.
